The results of the randomized, placebo-controlled, double-blind trial of the tau-targeting drug Semorinemab indicate that it failed to slow functional decline in patients with moderate to mild AD, suggesting the need for further exploration of its effects at different stages of the disease or in combination with other therapeutic modalities [276]. Here, MAPT is linked to Alzheimer disease.